{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:20:45Z","timestamp":1791519645707,"version":"4.3.4"},"reference-count":86,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The worldwide scenario of antibiotic resistance and the falling number of funds for the development of novel antibiotics have led research efforts toward the study of specific cost-effective strategies aimed at discovering drugs against microbial infections. Among the potential options, drug repositioning, which has already exhibited satisfactory results in other medical fields, came out as the most promising. It consists of finding new uses for previously approved medicines and, over the years, many \u201crepurposed drugs\u201d displayed some encouraging in vitro and in vivo results beyond their initial application. The principal theoretical justification for reusing already existing drugs is that they have known mechanisms of action and manageable side effects. Reuse of old drugs is now considered an interesting approach to overcome the drawbacks of conventional antibiotics. The purpose of this review is to offer the reader a panoramic view of the updated studies concerning the repositioning process of different classes of non-antibiotic drugs in the antimicrobial field. Several research works reported the ability of some non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, antipsychotics, and statins to counteract the growth of harmful microorganisms, demonstrating an interesting winning mode to fight infectious diseases caused by antimicrobial resistant bacteria.<\/jats:p>","DOI":"10.3390\/antibiotics11060816","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:25:11Z","timestamp":1655443511000},"page":"816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach"],"prefix":"10.3390","volume":"11","author":[{"given":"Alexia","family":"Barbarossa","sequence":"first","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5462-4650","authenticated-orcid":false,"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-1103","authenticated-orcid":false,"given":"Filomena","family":"Corbo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-2197","authenticated-orcid":false,"given":"Maria Lisa","family":"Clodoveo","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4991-3962","authenticated-orcid":false,"given":"Giuseppe","family":"Fracchiolla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-6667","authenticated-orcid":false,"given":"Antonio","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-9292","authenticated-orcid":false,"given":"Alessia","family":"Carocci","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13321-020-00450-7","article-title":"A review of computational drug repositioning: Strategies, approaches, opportunities, challenges, and directions","volume":"12","author":"Jarada","year":"2020","journal-title":"J. Cheminform."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.drudis.2012.12.009","article-title":"Predictive methods in drug repurposing: Gold mine or just a bigger haystack?","volume":"18","author":"Cavalla","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges, and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/0929867328666210623143526","article-title":"Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs","volume":"29","author":"Barbarossa","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118275","DOI":"10.1016\/j.lfs.2020.118275","article-title":"Utilizing drug repurposing against COVID-19\u2013Efficacy, limitations, and challenges","volume":"259","author":"Parvathaneni","year":"2020","journal-title":"Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1118","DOI":"10.1097\/IPC.0000000000001118","article-title":"Remdesivir, COVID-19, and Clinical Outcomes","volume":"30","author":"Mungmunpuntipantip","year":"2022","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"166294","DOI":"10.1016\/j.bbadis.2021.166294","article-title":"Repositioning Ivermectin for COVID-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication","volume":"1868","author":"Low","year":"2022","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","article-title":"Increased antimicrobial resistance during the COVID-19 pandemic","volume":"57","author":"Lai","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MCC.0000000000000755","article-title":"Antimicrobial resistance in ICUs: An update in the light of the COVID-19 pandemic","volume":"26","year":"2020","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jgar.2021.02.013","article-title":"Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic","volume":"25","author":"Rossolini","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/femsre\/fuaa001","article-title":"Antibiotic resistance: Turning evolutionary principles into clinical reality","volume":"44","author":"Andersson","year":"2020","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_13","first-page":"1914","article-title":"On behalf of the British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating antibacterial drug discovery and development","volume":"66","author":"Livermore","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2174\/1389450116666150806124110","article-title":"New antimicrobial approaches: Reuse of old drugs","volume":"17","author":"Savoia","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lagadinou, M., Onisor, M.O., Rigas, A., Musetescu, D.V., Gkentzi, D., Assimakopoulos, S.F., and Marangos, M. (2020). Antimicrobial properties on non-antibiotic drugs in the era of increased bacterial resistance. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030107"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Thakare, R., Kaul, G., Shukla, M., Kesharwani, P., Srinivas, N., Dasgupta, A., and Chopra, S. (2020). Repurposing Nonantibiotic Drugs as Antibacterials. Drug Discovery Targeting Drug-Resistant Bacteria, Academic Press.","DOI":"10.1016\/B978-0-12-818480-6.00005-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/fmb-2019-0346","article-title":"Diphenhydramine and levofloxacin combination therapy against antimicrobial resistance in respiratory tract infections","volume":"16","author":"Areej","year":"2021","journal-title":"Future Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4172\/pharmaceutical-sciences.1000288","article-title":"An exploratory study on the antimicrobial activity of cetirizine dihydrochloride","volume":"79","author":"Maji","year":"2017","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_20","first-page":"1000225","article-title":"Modulation of antibiotic efficacy against Klebsiella pneumoniae by antihistaminic drugs","volume":"5","author":"Sonbol","year":"2016","journal-title":"J. Med. Microb. Diagn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3389\/fmicb.2020.560798","article-title":"A novel promazine derivative shows high in vitro and in vivo antimicrobial activity against Staphylococcus aureus","volume":"11","author":"Ronco","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_22","first-page":"539","article-title":"In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-L-DOPA","volume":"19","author":"Dutta","year":"2005","journal-title":"In Vivo"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.micres.2004.10.002","article-title":"Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine","volume":"160","author":"Basu","year":"2005","journal-title":"Microbiol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2125.2007.03021.x","article-title":"Thioridazine: Resurrection as an antimicrobial agent?","volume":"64","author":"Thanacoody","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10096-011-1435-3","article-title":"Evidence of significant synergism between antibiotics and the antipsychotic, antimicrobial drug flupenthixol","volume":"31","author":"Jeyaseeli","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.9735\/0975-5276.5.4.430-434","article-title":"Experimental evaluation of synergistic action between antibiotics and the antipsychotic antimicrobial triflupromazine","volume":"5","author":"Debnath","year":"2013","journal-title":"Int. J. Microbiol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Le\u00e3o, C., Borges, A., and Sim\u00f5es, M. (2020). NSAIDs as a Drug Repurposing Strategy for Biofilm Control. Antibiotics, 9.","DOI":"10.3390\/antibiotics9090591"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.20546\/ijcmas.2018.712.042","article-title":"Non-antibiotic compounds: The activity of the NSAID diclofenac on bacteria\u2014A review","volume":"7","author":"Silva","year":"2018","journal-title":"Int. J. Curr. Microbiol. Appl. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","article-title":"Ibuprofen safety at the golden anniversary: Are all NSAIDs the same? A narrative review","volume":"37","author":"Varrassi","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1535370218787770","article-title":"Localized and targeted delivery of NSAIDs for treatment of inflammation: A review","volume":"244","author":"Haley","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejps.2015.02.011","article-title":"Antimicrobial activity of ibuprofen: New perspectives on an \u201cOld\u201d non-antibiotic drug","volume":"71","author":"Obad","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2174\/1389557520666200505124922","article-title":"Anticancer and antimicrobial activities of naproxen and naproxen derivatives","volume":"20","author":"Han","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01574-17","DOI":"10.1128\/AAC.01574-17","article-title":"Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens","volume":"62","author":"Shah","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rodrigues, M.E., Gomes, F., and Rodrigues, C.F. (2020). Candida spp.\/bacteria mixed biofilms. J. Fungi, 6.","DOI":"10.3390\/jof6010005"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.bmc.2016.01.026","article-title":"In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of Candida spp.","volume":"24","author":"Rosato","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rosato, A., Altini, E., Sblano, S., Salvagno, L., Maggi, F., de Michele, G., Carocci, A., Clodoveo, M.L., Corbo, F., and Fracchiolla, G. (2021). Synergistic Activity of New Diclofenac and Essential Oils Combinations against Different Candida spp.. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060688"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.joen.2021.04.004","article-title":"Antibiofilm Activity of Diclofenac and Antibiotic Solutions in Endodontic Therapy","volume":"47","author":"Baca","year":"2021","journal-title":"J. Endod."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chemosphere.2018.07.034","article-title":"The combined toxicity of UV\/chlorinated products from binary ibuprofen (IBP) and tyrosine (Tyr) on Escherichia coli: Emphasis on their occurrence and underlying mechanism","volume":"210","author":"Chen","year":"2018","journal-title":"Chemosphere"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107891","DOI":"10.1016\/j.carres.2019.107891","article-title":"Antibacterial effects and ibuprofen release potential using chitosan microspheres loaded with silver nanoparticles","volume":"488","author":"Pereira","year":"2020","journal-title":"Carbohydr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s42003-019-0530-3","article-title":"Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice","volume":"2","author":"Mortensen","year":"2019","journal-title":"Commun. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Caldara, M., and Marmiroli, N. (2021). Antimicrobial Properties of Antidepressants and Antipsychotics\u2014Possibilities and Implications. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090915"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1177\/0004867419877954","article-title":"A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome","volume":"53","author":"McGovern","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1097\/MJT.0000000000001022","article-title":"Antimicrobial and antineoplastic properties of sertraline","volume":"27","author":"Bottega","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_44","first-page":"4","article-title":"Sertraline enhances the activity of antimicrobial agents against pathogens of clinical relevance","volume":"22","author":"Ayaz","year":"2015","journal-title":"J. Biol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20510\/ukjpb\/6\/i1\/173522","article-title":"Study on antimicrobial potential of selected non-antibiotics and its interaction with conventional antibiotics","volume":"6","author":"Hadera","year":"2018","journal-title":"Pharm. Biosci. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.micpath.2018.07.040","article-title":"New roles of fluoxetine in pharmacology: Antibacterial effect and modulation of antibiotic activity","volume":"123","author":"Rocha","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jam.14490","article-title":"Sertraline as a promising antifungal agent: Inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro","volume":"128","author":"Gowri","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Krzy\u017cek, P., Franiczek, R., Krzy\u017canowska, B., \u0141aczma\u0144ski, \u0141., Migda\u0142, P., and Go\u015bciniak, G. (2019). In vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Pathogens, 8.","DOI":"10.3390\/pathogens8040228"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00044-020-02507-6","article-title":"Repositioning of fluoxetine and paroxetine: Study of potential antibacterial activity and its combination with ciprofloxacin","volume":"29","author":"Foletto","year":"2020","journal-title":"Med. Chem. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00044-019-02470-x","article-title":"In vitro evaluation of the antibacterial activity of amitriptyline and its synergistic effect with ciprofloxacin, sulfamethoxazole\u2013trimethoprim, and colistin as an alternative in drug repositioning","volume":"29","author":"Machado","year":"2020","journal-title":"Med. Chem. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.micpath.2018.11.056","article-title":"A mechanistic approach to the in-vitro resistance modulating effects of fluoxetine against meticillin resistant Staphylococcus aureus strains","volume":"127","author":"Josino","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1021\/acs.jproteome.5b01037","article-title":"Thioridazine alters the cell-envelope permeability of Mycobacterium tuberculosis","volume":"15","author":"Mulder","year":"2016","journal-title":"J. Proteome Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Amaral, L., and Viveiros, M. (2017). Thioridazine: A non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action. Antibiotics, 6.","DOI":"10.3390\/antibiotics6010003"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00181-20","DOI":"10.1128\/AAC.00181-20","article-title":"Thioridazine is an efflux pump inhibitor in Mycobacterium avium complex but of limited clinical relevance","volume":"64","author":"Ruth","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nistorescu, S., Gradisteanu Pircalabioru, G., Udrea, A.M., Simon, A., Pascu, M.L., and Chifiriuc, M.C. (2020). Laser-Irradiated Chlorpromazine as a Potent Anti-Biofilm Agent for Coating of Biomedical Devices. Coatings, 10.","DOI":"10.3390\/coatings10121230"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1806024","DOI":"10.1002\/adma.201806024","article-title":"A Biomimetic Non-Antibiotic Approach to Eradicate Drug-Resistant Infections","volume":"31","author":"Zhao","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"051002","DOI":"10.1117\/1.JBO.20.5.051002","article-title":"Characterization of mixtures of compounds produced in chlorpromazine aqueous solutions by ultraviolet laser irradiation: Their applications in antimicrobial assays","volume":"20","author":"Alexandru","year":"2014","journal-title":"J. Biomed. Opt."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.micpath.2019.02.012","article-title":"In vitro antimicrobial efficacy of laser exposed chlorpromazine against Gram-positive bacteria in planktonic and biofilm growth state","volume":"129","author":"Tozar","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2217\/fmb-2019-0092","article-title":"Chlorpromazine-impregnated catheters as a potential strategy to control biofilm-associated urinary tract infections","volume":"14","author":"Sidrim","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18043","DOI":"10.1038\/s41598-020-74752-z","article-title":"Anti-staphylococcal activity and mode of action of thioridazine photoproducts","volume":"10","author":"Tozar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkm496","article-title":"Unexpected antimicrobial effect of statins","volume":"61","author":"Jerwood","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Graziano, T.S., Cuzzullin, M.C., Franco, G.C., Schwartz-Filho, H.O., de Andrade, E.D., Groppo, F.C., and Cogo-Mueller, K. (2015). Statins and antimicrobial effects: Simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128098"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"22571","DOI":"10.1038\/srep22571","article-title":"Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens","volume":"6","author":"Thangamani","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_64","first-page":"13","article-title":"Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin","volume":"11","author":"Masadeh","year":"2012","journal-title":"Ann. Clin. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10096-018-3227-5","article-title":"In vitro antibacterial effects of statins against bacterial pathogens causing skin infections","volume":"37","author":"Ko","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"105019","DOI":"10.1016\/j.chemphyslip.2020.105019","article-title":"Optimization, physicochemical characterization, and antimicrobial activity of a novel simvastatin nano-niosomal gel against E. coli and S. aureus","volume":"234","author":"Akbarzadeh","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1080\/09205063.2020.1811188","article-title":"Simvastatin enhanced antimicrobial effect of Ag+ against E. faecalis infection of dentine through PLGA co-delivery submicron particles","volume":"31","author":"Fan","year":"2020","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.2147\/IJN.S211756","article-title":"New approach for simvastatin as an antibacterial: Synergistic effect with bio-synthesized silver nanoparticles against multidrug-resistant bacteria","volume":"14","author":"Figueiredo","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e17369","DOI":"10.1590\/s2175-97902018000217369","article-title":"Synergistic antibacterial effect of statins with the complex {[1-(4-bromophenyl)-3-phenyltriazene N3-oxide-\u03ba2 N1, O4](dimethylbenzylamine-\u03ba2 C1, N4) palladium (II)}","volume":"54","author":"Rampelotto","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jgh.14810","article-title":"Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial","volume":"35","author":"Sarkeshikian","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e01674-17","DOI":"10.1128\/AAC.01674-17","article-title":"A drug repositioning approach reveals that Streptococcus mutans is susceptible to a diverse range of established antimicrobials and nonantibiotics","volume":"62","author":"Saputo","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1128\/AAC.00692-15","article-title":"Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner","volume":"59","author":"Dalecki","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10534-014-9743-6","article-title":"Drug repositioning: Auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections","volume":"27","author":"Cassetta","year":"2014","journal-title":"Biometals"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/1521-3773(20000818)39:16<2931::AID-ANIE2931>3.0.CO;2-W","article-title":"First crystal structure of a medicinally relevant gold protein complex: Unexpected binding of [Au(PEt3)]+ to histidine","volume":"39","author":"Zou","year":"2000","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"28977","DOI":"10.1074\/jbc.M109.020701","article-title":"Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: Structural and kinetic aspects","volume":"284","author":"Angelucci","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.01675-12","article-title":"A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia","volume":"57","author":"Miyamoto","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dky555","article-title":"Repurposing Ethyl Bromopyruvate as a Broad-Spectrum Antibacterial","volume":"74","author":"Kumar","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0099-5428(05)32002-8","article-title":"Niclosamide: Comprehensive profile","volume":"32","year":"2005","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rajamuthiah, R., Fuchs, B.B., Conery, A.L., Kim, W., Jayamani, E., Kwon, B., Ausubel, F.M., and Mylonakis, E. (2015). Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124595"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1038\/s41598-018-22037-x","article-title":"Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori","volume":"8","author":"Tharmalingam","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fcimb.2018.00348","article-title":"Synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae","volume":"8","author":"Pachon","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bjid.2017.01.001","article-title":"Protective effect of metformin against tuberculosis infections in diabetic patients: An observational study of south Indian tertiary healthcare facility","volume":"21","author":"Marupuru","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cid\/cix819","article-title":"Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment","volume":"66","author":"Degner","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10096-018-3242-6","article-title":"Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: Experiences from 3-year follow-up","volume":"37","author":"Ma","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"He, X., Jin, S., Fan, W., and Fan, B. (2022). Synergistic In vitro Antimicrobial Activity of Triton X-100 and Metformin against Enterococcus faecalis in Normal and High-Glucose Conditions. Microorganisms, 10.","DOI":"10.3390\/microorganisms10010124"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/816\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:33:44Z","timestamp":1760139224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":86,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060816"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060816","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}